徐璐璐,沈伟伟,陈潇潇,李桂霞,许圆圆,高眉扬,周素娟,林海江,何纳.台州市2016-2018年新报告HIV/AIDS抗病毒治疗前HIV-1耐药及亚型流行特征分析[J].Chinese journal of Epidemiology,2021,42(4):711-715 |
台州市2016-2018年新报告HIV/AIDS抗病毒治疗前HIV-1耐药及亚型流行特征分析 |
HIV-1 drug resistance and subtypes in newly reported HIV/AIDS patients before antiretroviral therapy in Taizhou city, 2016-2018 |
Received:July 06, 2020 |
DOI:10.3760/cma.j.cn112338-20200706-00926 |
KeyWord: 艾滋病病毒/艾滋病 亚型 耐药 |
English Key Word: HIV/AIDS Subtype Drug resistance |
FundProject:国家科技重大专项(2018ZX10721102-004);上海市卫生健康委课题(GWTD2015S05) |
Author Name | Affiliation | E-mail | Xu Lulu | Department of Epidemiology, School of Public Health, Key Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai 200032, China | | Shen Weiwei | Taizhou City Center for Disease Control and Prevention, Taizhou 318000, China | | Chen Xiaoxiao | Taizhou City Center for Disease Control and Prevention, Taizhou 318000, China | | Li Guixia | Taizhou City Center for Disease Control and Prevention, Taizhou 318000, China | | Xu Yuanyuan | Taizhou City Center for Disease Control and Prevention, Taizhou 318000, China | | Gao Meiyang | Department of Epidemiology, School of Public Health, Key Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai 200032, China | | Zhou Sujuan | Department of Epidemiology, School of Public Health, Key Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai 200032, China | | Lin Haijiang | Taizhou City Center for Disease Control and Prevention, Taizhou 318000, China | fudanlhj@qq.com | He Na | Department of Epidemiology, School of Public Health, Key Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai 200032, China | nhe@fudan.edu.cn |
|
Hits: 2367 |
Download times: 1006 |
Abstract: |
目的 了解台州市新报告HIV/AIDS抗病毒治疗(ART)前HIV-1耐药情况及亚型流行特点。方法 于2016年1月至2018年12月在台州市开展新报告HIV/AIDS在ART前HIV-1耐药的横断面调查,RT-PCR扩增获得HIV-1 pol基因片段并测序,提交序列至斯坦福大学耐药数据库,根据2014年WHO耐药监测指南的推荐标准,确定耐药突变位点以及HIV-1毒株对抗病毒药物的敏感性。结果 2016-2018年台州市新报告HIV/AIDS中成功获得HIV-1 pol基因区序列的研究对象806例,ART前HIV-1耐药率为2.9%(23/806),其中,非核苷类反转录酶抑制剂(NNRTIs)、核苷类反转录酶抑制剂(NRTIs)和蛋白酶抑制剂(PIs)耐药率分别为1.9%(15/806)、0.6%(5/806)和0.0%。2016-2018年新报告HIV/AIDS在ART前HIV-1耐药率依次分别为1.6%、1.8%和4.8%。NNRTIs和NRTIs耐药突变位点以K103 N(0.7%)和M184I/V(0.5%)为主。HIV-1亚型以CRF01_AE(42.7%,344/806)、CRF07_BC(28.9%,233/806)和CRF08_BC(11.2%,90/806)为主。同性性传播者HIV-1亚型以CRF01_AE(53.3%,136/255)和CRF07_BC(32.2%,82/255)为主;异性性传播者HIV-1亚型以CRF01_AE(37.7%,203/539)、CRF07_BC(27.5%,148/539)和CRF08_BC(16.1%,87/539)为主。结论 2016-2018年台州市新报告HIV/AIDS在ART前HIV-1耐药率处于低流行状态,但存在上升趋势,需加强对HIV-1耐药型毒株的监测工作。 |
English Abstract: |
Objective To explore the HIV-1 drug resistance and subtypes in newly reported HIV/AIDS patients before antiretroviral therapy (ART) in Taizhou city. Methods A cross-sectional study of HIV-1 drug resistance was conducted among newly reported HIV/AIDS patients before ART in Taizhou from January 2016 to December 2018. HIV-1 pol gene sequences were obtained by RT-PCR. The sequences were submitted to the Stanford University drug resistance database. The drug resistance mutation and the sensitivity of HIV-1 strains to antiretroviral drugs were determined according to WHO Guidelines on HIV drug resistance surveillance of 2014. Results A total of 806 HIV-1 pol gene sequences were obtained successfully. The overall HIV-1 drug resistance rate was 2.9% (23/806), 1.9% for non-nucleoside reverse transcriptase inhibitors (NNRTIs), 0.6% for nucleoside reverse transcriptase inhibitors (NRTIs), and 0.0% for protease inhibitors (PIs), respectively. From 2016 to 2018, the HIV-1 drug resistance rate was 1.6%, 1.8%, and 4.8%, respectively. The resistance mutations of NNRTIs and NRTIs were mainly K103 N (0.7%) and M184I/V (0.5%). HIV-1 subtypes were mostly CRF01_AE (42.7%,344/806),CRF07_BC (28.9%,233/806) and CRF08_BC (11.2%,90/806).HIV-1 subtypes among homosexually transmitted infections were mostly CRF01_AE (53.3%, 136/255) and CRF07_BC (32.2%, 82/255), and HIV-1 subtypes among heterosexually transmitted infections were mainly CRF01_AE (37.7%, 203/539), CRF07_BC (27.5%, 148/539) and CRF08_BC (16.1%, 87/539). Conclusion HIV-1 drug resistance rate among newly reported HIV/AIDS patients before ART remained low in Taizhou during 2016 to 2018, an increasing trend seemed to be notifiable and warrants continuous surveillance of HIV-1 drug resistance. |
View Fulltext
Html FullText
View/Add Comment Download reader |
Close |
|
|
|